NASDAQ:VRTX

Vertex Pharmaceuticals Stock Forecast, Price & News

$184.92
+0.65 (+0.35 %)
(As of 09/23/2021 03:58 PM ET)
Add
Compare
Today's Range
$184.50
$186.45
50-Day Range
$184.27
$202.99
52-Week Range
$182.60
$280.99
Volume44,059 shs
Average Volume2.02 million shs
Market Capitalization$47.97 billion
P/E Ratio24.40
Dividend YieldN/A
Beta0.63
30 days | 90 days | 365 days | Advanced Chart
Receive VRTX News and Ratings via Email

Sign-up to receive the latest news and ratings for Vertex Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Vertex Pharmaceuticals logo

About Vertex Pharmaceuticals

Vertex Pharmaceuticals, Inc. is a global biotechnology company. It engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Social Links


MarketRank

Overall MarketRank

2.78 out of 5 stars

Medical Sector

29th out of 1,351 stocks

Pharmaceutical Preparations Industry

12th out of 664 stocks

Analyst Opinion: 4.3Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 1.3 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Vertex Pharmaceuticals (NASDAQ:VRTX) Frequently Asked Questions

Is Vertex Pharmaceuticals a buy right now?

22 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Vertex Pharmaceuticals in the last twelve months. There are currently 2 sell ratings, 4 hold ratings and 16 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Vertex Pharmaceuticals stock.
View analyst ratings for Vertex Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Vertex Pharmaceuticals?

Wall Street analysts have given Vertex Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Vertex Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Vertex Pharmaceuticals?

Vertex Pharmaceuticals saw a increase in short interest in the month of August. As of August 13th, there was short interest totaling 5,040,000 shares, an increase of 20.3% from the July 29th total of 4,190,000 shares. Based on an average daily volume of 2,450,000 shares, the days-to-cover ratio is presently 2.1 days. Currently, 2.0% of the company's stock are short sold.
View Vertex Pharmaceuticals' Short Interest
.

When is Vertex Pharmaceuticals' next earnings date?

Vertex Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Vertex Pharmaceuticals
.

How were Vertex Pharmaceuticals' earnings last quarter?

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) released its quarterly earnings data on Thursday, July, 29th. The pharmaceutical company reported $3.11 earnings per share for the quarter, beating the consensus estimate of $2.25 by $0.86. The pharmaceutical company earned $1.79 billion during the quarter, compared to analyst estimates of $1.71 billion. Vertex Pharmaceuticals had a trailing twelve-month return on equity of 29.73% and a net margin of 29.80%.
View Vertex Pharmaceuticals' earnings history
.

How has Vertex Pharmaceuticals' stock been impacted by Coronavirus?

Vertex Pharmaceuticals' stock was trading at $220.34 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, VRTX shares have decreased by 15.7% and is now trading at $185.71.
View which stocks have been most impacted by COVID-19
.

What guidance has Vertex Pharmaceuticals issued on next quarter's earnings?

Vertex Pharmaceuticals issued an update on its FY 2021 earnings guidance on Thursday, August, 5th. The company provided EPS guidance of for the period. The company issued revenue guidance of $7.20 billion-$7.40 billion, compared to the consensus revenue estimate of $6.99 billion.

What price target have analysts set for VRTX?

22 Wall Street analysts have issued 12 month price targets for Vertex Pharmaceuticals' shares. Their forecasts range from $175.00 to $331.00. On average, they expect Vertex Pharmaceuticals' stock price to reach $266.61 in the next year. This suggests a possible upside of 43.6% from the stock's current price.
View analysts' price targets for Vertex Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Vertex Pharmaceuticals' key executives?

Vertex Pharmaceuticals' management team includes the following people:
  • Reshma Kewalramani, President, Chief Executive Officer & Director (LinkedIn Profile)
  • Stuart A. Arbuckle, Chief Operating Officer & Executive Vice President
  • Charles F. Wagner, Chief Financial Officer & Executive Vice President
  • David Matthew Altshuler, Chief Scientific Officer & EVP-Global Research
  • Mike Tirozzi, Senior VP, Chief Information & Data Officer

What is Reshma Kewalramani's approval rating as Vertex Pharmaceuticals' CEO?

31 employees have rated Vertex Pharmaceuticals CEO Reshma Kewalramani on Glassdoor.com. Reshma Kewalramani has an approval rating of 76% among Vertex Pharmaceuticals' employees.

What other stocks do shareholders of Vertex Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vertex Pharmaceuticals investors own include NVIDIA (NVDA), Companhia de Saneamento Básico do Estado de São Paulo - SABESP (SBS), Alibaba Group (BABA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Micron Technology (MU), salesforce.com (CRM), Netflix (NFLX), Intel (INTC) and PayPal (PYPL).

What is Vertex Pharmaceuticals' stock symbol?

Vertex Pharmaceuticals trades on the NASDAQ under the ticker symbol "VRTX."

Who are Vertex Pharmaceuticals' major shareholders?

Vertex Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (9.00%), Vanguard Group Inc. (7.81%), Price T Rowe Associates Inc. MD (5.05%), State Street Corp (4.51%), Alliancebernstein L.P. (2.46%) and FMR LLC (2.25%). Company insiders that own Vertex Pharmaceuticals stock include Amit Sachdev, Bastiano Sanna, Bruce I Sachs, Charles F Wagner Jr, David Altshuler, Jeffrey M Leiden, Margaret G Mcglynn, Michael Parini, Ourania Tatsis, Paul M Silva, Reshma Kewalramani, Sangeeta N Bhatia, Sangeeta N Bhatia, Stuart A Arbuckle, William D Young and Yuchun Lee.
View institutional ownership trends for Vertex Pharmaceuticals
.

Which major investors are selling Vertex Pharmaceuticals stock?

VRTX stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Price T Rowe Associates Inc. MD, Capital International Investors, Alliancebernstein L.P., BlackRock Inc., Avoro Capital Advisors LLC, Point72 Asset Management L.P., and Clearbridge Investments LLC. Company insiders that have sold Vertex Pharmaceuticals company stock in the last year include Amit Sachdev, Bastiano Sanna, Michael Parini, Paul M Silva, Sangeeta N Bhatia, and Stuart A Arbuckle.
View insider buying and selling activity for Vertex Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Vertex Pharmaceuticals stock?

VRTX stock was bought by a variety of institutional investors in the last quarter, including Jefferies Group LLC, Macquarie Group Ltd., Deutsche Bank AG, Amundi, Impax Asset Management Group plc, Parnassus Investments CA, Canada Pension Plan Investment Board, and State Street Corp. Company insiders that have bought Vertex Pharmaceuticals stock in the last two years include Bruce I Sachs, and Reshma Kewalramani.
View insider buying and selling activity for Vertex Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Vertex Pharmaceuticals?

Shares of VRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vertex Pharmaceuticals' stock price today?

One share of VRTX stock can currently be purchased for approximately $185.71.

How much money does Vertex Pharmaceuticals make?

Vertex Pharmaceuticals has a market capitalization of $48.18 billion and generates $6.21 billion in revenue each year. The pharmaceutical company earns $2.71 billion in net income (profit) each year or $9.03 on an earnings per share basis.

How many employees does Vertex Pharmaceuticals have?

Vertex Pharmaceuticals employs 3,400 workers across the globe.

Does Vertex Pharmaceuticals have any subsidiaries?

The following companies are subsidiares of Vertex Pharmaceuticals: Aurora Biosciences Corporation, Exonics Therapeutics, Semma Therapeutics, The Vertex Foundation Inc., Torreyana Insurance Company Inc., Vertex Farmaceutica do Brasil LTDA, Vertex Holdings Inc., Vertex Pharmaceuticals (Australia) Pty. Ltd., Vertex Pharmaceuticals (CH) GmbH, Vertex Pharmaceuticals (Canada) Incorporated, Vertex Pharmaceuticals (Cayman 509) Limited, Vertex Pharmaceuticals (Cayman 765) Limited, Vertex Pharmaceuticals (Cayman 787) Limited, Vertex Pharmaceuticals (Cayman II) Limited, Vertex Pharmaceuticals (Cayman III) Limited, Vertex Pharmaceuticals (Cayman) Limited, Vertex Pharmaceuticals (Czech Republic) s.r.o, Vertex Pharmaceuticals (Delaware) LLC, Vertex Pharmaceuticals (Distribution) Incorporated, Vertex Pharmaceuticals (Europe) Limited, Vertex Pharmaceuticals (France) SAS, Vertex Pharmaceuticals (Germany) GmbH, Vertex Pharmaceuticals (Ireland) Limited, Vertex Pharmaceuticals (Italy) S.r.L., Vertex Pharmaceuticals (Netherlands) B.V., Vertex Pharmaceuticals (Poland) sp. z.o.o, Vertex Pharmaceuticals (Portugal) Unipessoal Lda., Vertex Pharmaceuticals (Puerto Rico) LLC, Vertex Pharmaceuticals (San Diego) LLC, Vertex Pharmaceuticals (Singapore) Pte. Ltd., Vertex Pharmaceuticals (Spain) S.L., Vertex Pharmaceuticals (Sweden) AB, Vertex Pharmaceuticals (Switzerland) Sàrl, Vertex Pharmaceuticals (U.K.) Limited, Vertex Pharmaceuticals GmbH, Vertex Pharmaceuticals Single Member Societe Anonyme, and Vertex Securities Corporation.

When was Vertex Pharmaceuticals founded?

Vertex Pharmaceuticals was founded in 1989.

What is Vertex Pharmaceuticals' official website?

The official website for Vertex Pharmaceuticals is www.vrtx.com.

Where are Vertex Pharmaceuticals' headquarters?

Vertex Pharmaceuticals is headquartered at 50 NORTHERN AVENUE, BOSTON MA, 02210.

How can I contact Vertex Pharmaceuticals?

Vertex Pharmaceuticals' mailing address is 50 NORTHERN AVENUE, BOSTON MA, 02210. The pharmaceutical company can be reached via phone at (617) 341-6100 or via email at [email protected].


This page was last updated on 9/23/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.